Lisocabtagene maraleucel chimeric antigen receptor T-cell therapy significantly enhances treatment of relapsed/refractory B-cell malignancies, offering high response rates and durable remissions.
Sarah E. Medeiros, PharmD, BCOP
Advertisement
Articles by Sarah E. Medeiros, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Approves Imlunestrant Tablets for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
2
IMWG Consensus Risk Criteria Predicts Survival in Daratumumab Quadruplet Therapy
3
Linvoseltamab Monotherapy Elicits Promising ORR, MRD-Negativity in NDMM
4
How Pharmacists Support CDK4/6 Inhibitor Management and Patient Care
5
